Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects.
Standard
Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects. / Klink, Thorsten; Bela, C; Stoelting, S; Peters, S O; Broll, R; Wagner, T.
in: J CANCER RES CLIN, Jahrgang 132, Nr. 10, 10, 2006, S. 643-652.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects.
AU - Klink, Thorsten
AU - Bela, C
AU - Stoelting, S
AU - Peters, S O
AU - Broll, R
AU - Wagner, T
PY - 2006
Y1 - 2006
N2 - Recent studies of conventional chemotherapeutic drugs administered in metronomic therapy schedules showed remarkable inhibitory effects on tumor angiogenesis. Subsequent and prolonged tumor regression was achieved moreover by circumventing acquired drug resistance. In this study, metronomic and conventional trofosfamide were compared on human NSCLC xenograft "LX-1."
AB - Recent studies of conventional chemotherapeutic drugs administered in metronomic therapy schedules showed remarkable inhibitory effects on tumor angiogenesis. Subsequent and prolonged tumor regression was achieved moreover by circumventing acquired drug resistance. In this study, metronomic and conventional trofosfamide were compared on human NSCLC xenograft "LX-1."
KW - Animals
KW - Humans
KW - Female
KW - Time Factors
KW - Mice
KW - Tumor Cells, Cultured
KW - Drug Administration Schedule
KW - Apoptosis/drug effects
KW - Mice, Nude
KW - Xenograft Model Antitumor Assays
KW - Inhibitory Concentration 50
KW - Angiogenesis Inhibitors/administration & dosage/therapeutic use/toxicity
KW - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use/toxicity
KW - Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
KW - Cyclophosphamide/administration & dosage/analogs & derivatives/therapeutic use/toxicity
KW - Endothelial Cells/drug effects/metabolism
KW - Lung Neoplasms/drug therapy
KW - Animals
KW - Humans
KW - Female
KW - Time Factors
KW - Mice
KW - Tumor Cells, Cultured
KW - Drug Administration Schedule
KW - Apoptosis/drug effects
KW - Mice, Nude
KW - Xenograft Model Antitumor Assays
KW - Inhibitory Concentration 50
KW - Angiogenesis Inhibitors/administration & dosage/therapeutic use/toxicity
KW - Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use/toxicity
KW - Carcinoma, Non-Small-Cell Lung/drug therapy/pathology
KW - Cyclophosphamide/administration & dosage/analogs & derivatives/therapeutic use/toxicity
KW - Endothelial Cells/drug effects/metabolism
KW - Lung Neoplasms/drug therapy
M3 - SCORING: Journal article
VL - 132
SP - 643
EP - 652
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 10
M1 - 10
ER -